Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HBV vaccine (recombinant, E. coli)
- Development stage
- Preclinical
- Lead developer
- Merck
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A recombinant protein vaccine candidate for the prevention of hepatitis B infection, developed by Xiamen Wan Tai (also known as Beijing Wantai Biological Pharmacy). The vaccine utilizes an *Escherichia coli* expression system to produce the recombinant hepatitis B surface antigen (HBsAg), which serves as the active immunogen. This production platform distinguishes it from most commercially available hepatitis B vaccines that typically use yeast or mammalian cell systems. The vaccine is designed to elicit protective anti-HBs antibodies to prevent infection by the hepatitis B virus. It is currently in the preclinical stage of development.
- Other names
- HBV Vaccine (Recombinant, E. coli)Recombinant HBsAg (E. coli)hepatitis B vaccine (recombinant, E. coli)-Xiamen Wan Tai-HBV surface antigen (HBsAg)-recombinant protein vaccine-E. coli expression-Hepatitis B
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on HBV vaccine (recombinant, E. coli).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HBV vaccine (recombinant, E. coli).